Rockwell Medical, Inc.

Rockwell Medical, Inc.

RMTI
Rockwell Medical, Inc.US flagNASDAQ Capital Market
0.71
USD
-0.01
- -
27.99MMarket Cap
Rockwell Medical, Inc.
RMTI
(NASDAQ Capital Market)

Recent

price

0.71

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
39.06
30.39
26.88
17.48
14.4
12.24
11.54
12.4
13.2
11.07
9.05
7.26
7.38
3.58
3.27
1.93
1.81
Revenue per Share
-1.76
-13.31
-29.14
-16.28
-5.67
-3.19
-4.29
-5.61
-6.69
-6.16
-4.49
-3.83
-1.89
-0.36
-0.02
-0.15
-0.14
Basic EPS, GAAP
0.87
-7.04
-16.86
-17.13
0.95
-3.13
-2.77
-4.93
-4.46
-5.16
-4.46
-3.99
-1.74
-0.42
0.1
-0.03
0.05
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-22.66
7.09
-9.24
-1.45
18.3
13.99
11.67
7.13
-56.72
-55.35
-49.08
-43.4
-39.4
-17.03
-12.8
-11.2
-10.85
Book Value per Share
19.32
10.24
-6.23
-0.28
17.92
13.55
11.27
6.92
5.49
3.5
4.84
0.19
1.34
0.41
0.69
0.73
0.68
Tangible Book Value per Share
2
2
2
3
4
5
5
5
5
6
7
9
10
23
31
36
37
Basic Weighted Avg Shares
60
49
50
52
54
55
53
57
63
61
62
62
73
84
101
69
68
Sales/Revenue/Turnover
-4.82
-44.29
-108.87
-89.84
-32.4
-27.28
-37.93
-45.24
-49.55
-55.62
-45.69
-48.98
-23.05
-7.98
0.6
-6.77
-7.11
Operating Margin (%)
1
1
1
1
1
1
1
1
1
3
2
3
1
1
2
2
2
Depreciation Expense
-3
-21
-54
-49
-21
-14
-20
-26
-32
-34
-31
-33
-19
-8
- -
-5
-5
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-4.51
-43.79
-108.38
-93.13
-39.36
-26.05
-37.16
-45.24
-50.68
-55.67
-49.66
-52.76
-25.65
-10.09
-0.47
-7.67
-7.98
Profit Margin (%)
26
12
-14
14
85
77
68
40
34
24
57
14
18
12
23
29
27
Working Capital
- -
- -
- -
18
- -
- -
- -
- -
- -
2
23
19
12
11
11
11
12
LT Debt
31
18
-10
1
69
62
53
33
27
20
34
3
14
21
33
37
36
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
-21.83
-33.82
-59.72
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
2
3
LT Borrowings
9
9
8
LT Finance Leases
2
2
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
39
39
39
Market Capitalization
42
30
33

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
38
38
37
Cash, Cash Equivalents & STI
24
25
24
Accounts Receivable, Net
8
8
9
Inventories
4
3
3
Total Current Liabilities
10
10
10
Payables & Accruals
3
4
5
ST Debt
2
2
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
45.4%
96.27%
13.49%
Free Cash Flow
-24.94%
-70.54%
-137.64%
Net Income, GAAP
90.98%
164.18%
1,007.08%
Sales/Revenue/Turnover
3.42%
4.32%
-31.76%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
23
26
28
25
101
2025
19
16
16
18
69
2026
17
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.06
0.01
0.05
- -
-0.02
2025
-0.04
-0.04
-0.05
-0.01
-0.15
2026
-0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Rockwell Medical, Inc. (Nasdaq: RMTI) develops, manufactures, commercializes and distributes hemodialysis concentrates and specialty pharmaceutical products for dialysis providers serving patients with end-stage renal disease worldwide. The company offers a broad portfolio of hemodialysis solutions, including liquid and dry acid concentrates such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate and RenalPure acid concentrate; bicarbonate concentrates such as RenalPure bicarbonate concentrate, Sterilyte bicarbonate concentrate; hemodialysis concentrates including Centrisol and Renasol; the DAMX dry acid concentrate mixer and DAMX45 system; iron therapy products such as Triferic dialysate and IV for iron replacement to maintain hemoglobin levels; calcitriol, an active vitamin D generic for treating secondary hyperparathyroidism; and ancillary products including 5% acetic acid, cleaners, citric acid descaler, water softener salt pellets and dialysis kits. Rockwell Medical operates manufacturing and distribution facilities in the United States, serving dialysis clinics domestically and through distribution partners internationally with a focus on the U.S. outpatient market and expansion into Latin America; founded in 1996 and headquartered in Wixom, Michigan. In 2025, the company signed a three-year multi-million dollar partnership agreement with Innovative Renal Care, one of the largest U.S. dialysis providers, to supply liquid and dry acid and bicarbonate concentrates along with the DAMX system for use across IRC's facilities; entered a multi-year product purchase agreement with the world's leading dialysis products provider expected to generate over $10 million in net sales; secured several new long-term product purchasing agreements with university medical centers; and projects net sales of $65 million to $70 million for the year amid strategic shifts toward higher-margin products and at-home dialysis expansion.

Company News

APIChat
  • Rockwell Medical Renews Product Purchase Agreement with aQua Dialysis

  • Rockwell Medical Signs New 3-Year Product Purchase Agreement with Heritage Dialysis

  • Rockwell Medical Signs New 3-Year Product Purchase Agreement with Heritage Dialysis

  • Rockwell Medical, Inc. (RMTI) Q1 2026 Earnings Call Transcript

  • Rockwell Medical (RMTI) Reports Q1 Loss, Misses Revenue Estimates

  • Rockwell Medical Announces First Quarter 2026 Results and Additional 2026 Guidance with Focus on Profitability

  • Rockwell Medical to Release First Quarter 2026 Results on Thursday, May 7, 2026

  • Should Value Investors Buy Rockwell Medical (RMTI) Stock?

  • Fast-paced Momentum Stock Rockwell Medical (RMTI) Is Still Trading at a Bargain

  • Rockwell Medical, Inc. (RMTI) Q4 2025 Earnings Call Transcript

  • Rockwell Medical (RMTI) Reports Q4 Loss, Misses Revenue Estimates

  • Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results

  • Rockwell Medical to Release Fourth Quarter and Full-Year 2025 Results on Thursday, March 26, 2026

  • Why Fast-paced Mover Rockwell Medical (RMTI) Is a Great Choice for Value Investors

  • Are Investors Undervaluing Rockwell Medical (RMTI) Right Now?

  • Rockwell Medical Named 'Great Place to Work' for Fourth Year in a Row

  • Analyzing Rockwell Medical (NASDAQ:RMTI) & Senestech (NASDAQ:SNES)

  • Rockwell Medical (RMTI) Upgraded to Buy: Here's What You Should Know

  • Is Rockwell Medical (RMTI) Stock Undervalued Right Now?

  • Despite Fast-paced Momentum, Rockwell Medical (RMTI) Is Still a Bargain Stock